Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CYTOMEL | King Pharmaceuticals | N-010379 RX | 1982-01-01 | 3 products, RLD |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 4 | 2 | 4 | 1 | 6 | 15 |
Hypothyroidism | D007037 | EFO_0004705 | E03.9 | — | 4 | 1 | 3 | 8 | 15 |
Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 3 | — | 1 | 4 | 8 |
Depression | D003863 | — | F33.9 | — | — | 1 | 2 | 4 | 7 |
Euthyroid sick syndromes | D005067 | EFO_1000931 | E07.81 | — | 2 | — | 1 | 3 | 6 |
Cataract | D002386 | HP_0000518 | H26.9 | — | — | — | 2 | 3 | 5 |
Local anesthesia | D000772 | — | — | 1 | — | — | 2 | 1 | 4 |
Recurrence | D012008 | — | — | — | 1 | — | 1 | 1 | 3 |
General anesthesia | D000768 | — | — | — | — | — | 1 | 2 | 3 |
Systemic inflammatory response syndrome | D018746 | EFO_1001478 | R65.10 | — | — | — | 1 | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 8 | 2 | — | 15 | 25 |
Rectal neoplasms | D012004 | — | — | 2 | 9 | 1 | — | 4 | 16 |
Colorectal neoplasms | D015179 | — | — | — | 3 | 1 | — | 8 | 12 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | 2 | 2 | — | 3 | 8 |
Urinary bladder neoplasms | D001749 | — | C67 | — | 4 | 1 | — | 1 | 6 |
Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | 1 | — | 4 | 6 |
Anesthesia | D000758 | — | — | 1 | — | 1 | — | 4 | 6 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | 2 | — | 3 | 5 |
Nasopharyngeal neoplasms | D009303 | — | — | 2 | — | 2 | — | — | 4 |
Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | — | 2 | — | 1 | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 18 | 1 | — | — | 4 | 22 |
Stroke | D020521 | EFO_0000712 | I63.9 | 2 | 1 | — | — | 9 | 11 |
Postoperative pain | D010149 | — | G89.18 | 1 | 1 | — | — | 9 | 10 |
Neoplasms | D009369 | — | C80 | — | 3 | — | — | 5 | 8 |
Covid-19 | D000086382 | — | U07.1 | — | 2 | — | — | 5 | 7 |
Heart failure | D006333 | HP_0001635 | I50 | 3 | 4 | — | — | 3 | 7 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 3 | — | — | 2 | 6 |
Asthma | D001249 | EFO_0000270 | J45 | 1 | 3 | — | — | 3 | 6 |
Hallucinations | D006212 | HP_0000738 | F06.0 | — | 1 | — | — | 5 | 6 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 3 | — | — | 2 | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Analgesia | D000698 | — | — | 1 | — | — | — | 3 | 4 |
Hiv infections | D015658 | EFO_0000764 | B20 | 2 | — | — | — | 2 | 4 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | — | — | — | 3 | 4 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | 3 | 4 |
Musculoskeletal pain | D059352 | — | — | 1 | — | — | — | 2 | 3 |
Esophageal neoplasms | D004938 | — | C15 | 1 | — | — | — | 2 | 3 |
Allergic rhinitis | D065631 | — | J30.9 | 1 | — | — | — | 1 | 2 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | 1 | 2 |
Chronic pain | D059350 | HP_0012532 | — | 1 | — | — | — | 1 | 2 |
Fibromyalgia | D005356 | EFO_0005687 | M79.1 | 1 | — | — | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 8 | 8 |
Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 7 | 7 |
Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 5 | 5 |
Hyperhidrosis | D006945 | HP_0000975 | — | — | — | — | — | 5 | 5 |
Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | — | 5 | 5 |
Psychotic disorders | D011618 | — | F20.81 | — | — | — | — | 4 | 4 |
Traumatic brain injuries | D000070642 | — | S06 | — | — | — | — | 3 | 3 |
Autism spectrum disorder | D000067877 | HP_0000729 | F84.0 | — | — | — | — | 3 | 3 |
Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | — | — | 3 | 3 |
Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | — | — | — | 3 | 3 |
Drug common name | Liothyronine |
INN | liothyronine |
Description | 3,3',5-triiodo-L-thyronine is an iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism. It has a role as a thyroid hormone, a human metabolite and a mouse metabolite. It is an iodophenol, a 2-halophenol and an iodothyronine. It is a conjugate acid of a 3,3',5-triiodo-L-thyroninate. It is a tautomer of a 3,3',5-triiodo-L-thyronine zwitterion. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O |
PDB | — |
CAS-ID | 6893-02-3 |
RxCUI | — |
ChEMBL ID | CHEMBL1544 |
ChEBI ID | 18258 |
PubChem CID | 5920 |
DrugBank | DB00279 |
UNII ID | 06LU7C9H1V (ChemIDplus, GSRS) |